United States Biotechnology & Medical Research

Immunome Inc (IMNM)

Track

Track

Immunome Inc. experienced significant insider trading activity over the past ninety days, totaling twenty-nine transactions. All recorded movements involved planned or proposed sales, amounting to over thirty-one million dollars. These divestments occurred alongside a recent earnings report that missed expectations, despite the stock price rising thirty-eight percent during this period.
Ticker: IMNM Exchange: NAS
Preparing chart...
Download chart Copy chart image Copy link Share to X Share


• Purchase • Sale • Planned purchase • Planned sale Net purchase Net sale Buy signal Sell signal Earnings
Upgrade for signal details

Upgrade to see score, net flow, insiders and context.

Upgrade to see full signal details →

Insider trades have triggered activity signals for Immunome Inc. Upgrade to see score, net flow, insiders and the full signal context.

Open in Activity Signals screener →
Top insiders
Trades
Abbreviations B: Buy, S: Sell, PP: Planned purchase, PlS: Planned sale, PrS: Proposed sale, O: Option / Other
2.2
Higgins Jack Chief Scientific Officer Officer
Transaction date
Planned sale
Price
73.84
Quantity 69,980 -0.0%
Value US$4,190,478
2.2
Higgins Jack Officer Officer
Transaction date
Proposed sale
Price
394.01
Quantity 66,085
Value US$2,112,974
Barchas Isaac Non-Executive Director
Transaction date
Planned sale
Price
215.58
Quantity 5,832 -26.2%
Value US$1,807,502
Barchas Isaac Director Non-Executive Director
Transaction date
Proposed sale
Price
27.25
Quantity 11,048
Value US$301,058
Barchas Isaac Non-Executive Director
Transaction date
Planned sale
Price
26.23
Quantity 62,291 -100.0%
Value US$1,633,893
Barchas Isaac Non-Executive Director
Transaction date
Planned sale
Price
26.07
Quantity 10,125 -14.0%
Value US$263,959
Barchas Isaac Non-Executive Director
Transaction date
Planned sale
Price
26.06
Quantity 15,248 -17.4%
Value US$397,363
Barchas Isaac Non-Executive Director
Transaction date
Planned sale
Price
26.06
Quantity 20,840 -19.2%
Value US$543,090
ABHMC II, LLC Shareholder
Transaction date
Proposed sale
Price
25.52
Quantity 108,504
Value US$2,769,022
1.6
Horn Kinney CHIEF BUSINESS OFFICER Officer
Transaction date
Planned sale
Price
25.09
Quantity 90,616 -100.0%
Value US$2,273,555
1.6
Horn Kinney Officer Officer
Transaction date
Proposed sale
Price
25.09
Quantity 90,616
Value US$2,274,007
1.6
Horn Kinney CHIEF BUSINESS OFFICER Officer
Transaction date
Planned sale
Price
25.00
Quantity 1,092 -100.0%
Value US$27,300
Barchas Isaac Non-Executive Director
Transaction date
Planned sale
Price
24.20
Quantity 16,906 -13.5%
Value US$409,125
1.6
Horn Kinney Officer Officer
Transaction date
Proposed sale
Price
25.00
Quantity 1,092
Value US$27,300
Barchas Isaac Non-Executive Director
Transaction date
Planned sale
Price
24.11
Quantity 83,094 -39.9%
Value US$2,003,396
ABHMC II, LLC Shareholder
Transaction date
Proposed sale
Price
23.61
Quantity 100,000
Value US$2,361,000
2.2
Lechleider Robert Chief Medical Officer Officer
Transaction date
Planned sale
Price
23.44
Quantity 16,072 -50.4%
Value US$376,728
2.2
Lechleider Robert Chief Medical Officer Officer
Transaction date
Planned sale
Price
22.76
Quantity 16,214 -33.7%
Value US$369,031
2.2
Lechleider Robert Chief Medical Officer Officer
Transaction date
Planned sale
Price
21.95
Quantity 22,714 -32.1%
Value US$498,572
Barchas Isaac Non-Executive Director
Transaction date
Planned sale
Price
23.33
Quantity 24,335 -10.5%
Value US$567,736
Barchas Isaac Non-Executive Director
Transaction date
Planned sale
Price
22.35
Quantity 75,665 -24.5%
Value US$1,691,113
ABHMC II, LLC Shareholder
Transaction date
Proposed sale
Price
21.49
Quantity 100,000
Value US$2,149,000
2.2
Lechleider Robert Officer Officer
Transaction date
Proposed sale
Price
21.60
Quantity 55,000
Value US$1,188,000
Barchas Isaac Non-Executive Director
Transaction date
Planned sale
Price
21.12
Quantity 101,050 -24.7%
Value US$2,134,176
ABHMC II, LLC Shareholder
Transaction date
Proposed sale
Price
21.04
Quantity 100,000
Value US$2,104,000
2.2
Lechleider Robert Chief Medical Officer Officer
Transaction date
Planned sale
Price
20.66
Quantity 14,420 -47.7%
Value US$297,917
2.2
Lechleider Robert Chief Medical Officer Officer
Transaction date
Planned sale
Price
19.56
Quantity 40,580 -57.3%
Value US$793,745
2.2
Lechleider Robert Officer Officer
Transaction date
Proposed sale
Price
19.73
Quantity 55,000
Value US$1,085,150
3.3
Rosett Max Chief Financial Officer Officer
Transaction date
Planned sale
Price
18.23
Quantity 60,000 -52.6%
Value US$1,093,800
3.3
Rosett Max Officer Officer
Transaction date
Proposed sale
Price
18.63
Quantity 60,000
Value US$1,117,800
2.9
BIENAIME JEAN JACQUES Non-Executive Director
Transaction date
Purchase
Price
19.27
Quantity 1,000 +2.4%
Value US$19,270
2.9
BIENAIME JEAN JACQUES Non-Executive Director
Transaction date
Purchase
Price
19.27
Quantity 1,000 +2.4%
Value US$19,270
2.9
BIENAIME JEAN JACQUES Non-Executive Director
Transaction date
Purchase
Price
19.46
Quantity 3,500 +9.0%
Value US$68,110
2.9
BIENAIME JEAN JACQUES Non-Executive Director
Transaction date
Purchase
Price
19.46
Quantity 3,500 +9.0%
Value US$68,110
2.9
BIENAIME JEAN JACQUES Non-Executive Director
Transaction date
Purchase
Price
19.48
Quantity 6,000 +18.2%
Value US$116,880
2.9
BIENAIME JEAN JACQUES Non-Executive Director
Transaction date
Purchase
Price
19.48
Quantity 6,000 +18.2%
Value US$116,880
2.9
BIENAIME JEAN JACQUES Non-Executive Director
Transaction date
Sale
Price
19.41
Quantity 10,000 -23.3%
Value US$194,100
2.9
BIENAIME JEAN JACQUES Non-Executive Director
Transaction date
Sale
Price
19.41
Quantity 10,000 -23.3%
Value US$194,100
2.9
BIENAIME JEAN JACQUES Non-Executive Director
Transaction date
Sale
Price
19.44
Quantity 500 -1.2%
Value US$9,720
2.9
BIENAIME JEAN JACQUES Non-Executive Director
Transaction date
Sale
Price
19.44
Quantity 500 -1.2%
Value US$9,720
2.9
BIENAIME JEAN JACQUES Non-Executive Director
Transaction date
Purchase
Price
20.70
Quantity 5,000 +13.0%
Value US$103,500
2.2
Higgins Jack Chief Scientific Officer Officer
Transaction date
Planned sale
Price
21.64
Quantity 9,438 -30.0%
Value US$204,238
3.3
Rosett Max Chief Financial Officer Officer
Transaction date
Planned sale
Price
22.48
Quantity 1,344 -2.4%
Value US$30,213
3.3
Rosett Max Chief Financial Officer Officer
Transaction date
Planned sale
Price
21.91
Quantity 63,656 -53.5%
Value US$1,394,703
3.3
Rosett Max Officer Officer
Transaction date
Proposed sale
Price
21.92
Quantity 65,000
Value US$1,425,085
3.3
Rosett Max Officer Officer
Transaction date
Proposed sale
Price
72.67
Quantity 65,000
Value US$4,723,550
2.2
Higgins Jack Officer Officer
Transaction date
Proposed sale
Price
21.64
Quantity 9,438
Value US$204,238
3.3
SIEGALL CLAY B President and CEO Executive Director
Transaction date
Purchase
Price
19.67
Quantity 25,450 +3.8%
Value US$500,602
1.8
WAGENHEIM PHILIP Non-Executive Director
Transaction date
Sale
Price
20.65
Quantity 28,200 -7.6%
Value US$582,330
1.8
WAGENHEIM PHILIP Non-Executive Director
Transaction date
Sale
Price
20.47
Quantity 36,800 -9.1%
Value US$753,296
1.8
WAGENHEIM PHILIP Director Non-Executive Director
Transaction date
Proposed sale
Price
20.81
Quantity 65,000
Value US$1,352,640
2.9
BIENAIME JEAN JACQUES Non-Executive Director
Transaction date
Purchase
Price
21.55
Quantity 1,000 +2.7%
Value US$21,550
2.9
BIENAIME JEAN JACQUES Non-Executive Director
Transaction date
Purchase
Price
22.12
Quantity 1,000 +2.7%
Value US$22,120
3.3
SIEGALL CLAY B President and CEO Executive Director
Transaction date
Purchase
Price
21.15
Quantity 4,729 +0.7%
Value US$100,018
Barchas Isaac Non-Executive Director
Transaction date
Planned sale
Price
22.34
Quantity 11,251 -0.6%
Value US$251,347
Barchas Isaac Non-Executive Director
Transaction date
Planned sale
Price
21.72
Quantity 371,949 -15.4%
Value US$8,078,732
3.3
SIEGALL CLAY B President and CEO Executive Director
Transaction date
Purchase
Price
20.48
Quantity 7,278 +0.9%
Value US$149,053
3.5
Tsai Philip Chief Technical Officer Officer
Transaction date
Purchase
Price
20.49
Quantity 10,000 +30.0%
Value US$204,900
3.3
SIEGALL CLAY B President and CEO Executive Director
Transaction date
Purchase
Price
21.50
Quantity 46,511 +5.8%
Value US$999,986
2.9
BIENAIME JEAN JACQUES Non-Executive Director
Transaction date
Purchase
Price
9.38
Quantity 5,000 +15.9%
Value US$46,900
3.3
SIEGALL CLAY B President and CEO Executive Director
Transaction date
Purchase
Price
7.29
Quantity 137,100 +20.5%
Value US$999,459
2.9
BIENAIME JEAN JACQUES Non-Executive Director
Transaction date
Purchase
Price
7.78
Quantity 7,800 +33.0%
Value US$60,684
2.9
BIENAIME JEAN JACQUES Non-Executive Director
Transaction date
Purchase
Price
8.21
Quantity 7,000 +42.1%
Value US$57,470
3.5
Tsai Philip Chief Technology Officer Officer
Transaction date
Purchase
Price
8.42
Quantity 12,300 +58.6%
Value US$103,566
3.3
SIEGALL CLAY B President and CEO Executive Director
Transaction date
Purchase
Price
7.75
Quantity 150,000 +28.9%
Value US$1,162,500
3.3
SIEGALL CLAY B President and CEO Executive Director
Transaction date
Purchase
Price
9.78
Quantity 33,943 +7.0%
Value US$331,918
3.3
SIEGALL CLAY B President and CEO Executive Director
Transaction date
Purchase
Price
9.54
Quantity 66,057 +15.7%
Value US$630,263
2.2
Lechleider Robert Chief Medical Officer Officer
Transaction date
Purchase
Price
9.48
Quantity 15,805 +inf%
Value US$149,800
3.5
Tsai Philip Chief Technology Officer Officer
Transaction date
Purchase
Price
9.43
Quantity 21,000 +inf%
Value US$198,030
3.3
Rosett Max Chief Financial Officer Officer
Transaction date
Sale
Price
16.01
Quantity 14,380 -23.2%
Value US$230,224
3.3
Rosett Max Officer Officer
Transaction date
Proposed sale
Price
16.01
Quantity 14,380
Value US$230,211
2.9
BIENAIME JEAN JACQUES Non-Executive Director
Transaction date
Purchase
Price
13.94
Quantity 7,000 +72.8%
Value US$97,608
2.2
Higgins Jack Chief Scientific Officer Officer
Transaction date
Sale
Price
13.93
Quantity 3,524 -18.0%
Value US$49,072
2.2
Higgins Jack Officer Officer
Transaction date
Proposed sale
Price
13.93
Quantity 3,524
Value US$49,073
Notification date Transaction date B/S Transaction type Insider and/or position Nb. shares
Price
Value 		Number of shares Price Value Details
2026-09-15 2026-09-11 PlS Planned sale
2.2
Higgins Jack

Chief Scientific Officer

Officer
69,980 -0.0%
73.84
US$4,190,478 		69,980 -0.0% 73.84 US$4,190,478
2026-09-11 2026-09-11 PrS Proposed sale
2.2
Higgins Jack

Officer

Officer
66,085
394.01
US$2,112,974 		66,085 394.01 US$2,112,974
2026-08-12 2026-08-12 PlS Planned sale
Barchas Isaac
Non-Executive Director
5,832 -26.2%
215.58
US$1,807,502 		5,832 -26.2% 215.58 US$1,807,502
2026-08-12 2026-08-12 PrS Proposed sale
Barchas Isaac

Director

Non-Executive Director
11,048
27.25
US$301,058 		11,048 27.25 US$301,058
2026-08-12 2026-08-11 PlS Planned sale
Barchas Isaac
Non-Executive Director
62,291 -100.0%
26.23
US$1,633,893 		62,291 -100.0% 26.23 US$1,633,893
2026-08-12 2026-08-10 PlS Planned sale
Barchas Isaac
Non-Executive Director
10,125 -14.0%
26.07
US$263,959 		10,125 -14.0% 26.07 US$263,959
2026-08-10 2026-08-07 PlS Planned sale
Barchas Isaac
Non-Executive Director
15,248 -17.4%
26.06
US$397,363 		15,248 -17.4% 26.06 US$397,363
2026-08-10 2026-08-06 PlS Planned sale
Barchas Isaac
Non-Executive Director
20,840 -19.2%
26.06
US$543,090 		20,840 -19.2% 26.06 US$543,090
2026-08-06 2026-08-06 PrS Proposed sale
ABHMC II, LLC

Shareholder
108,504
25.52
US$2,769,022 		108,504 25.52 US$2,769,022
2026-08-06 2026-08-04 PlS Planned sale
1.6
Horn Kinney

CHIEF BUSINESS OFFICER

Officer
90,616 -100.0%
25.09
US$2,273,555 		90,616 -100.0% 25.09 US$2,273,555
2026-08-04 2026-08-04 PrS Proposed sale
1.6
Horn Kinney

Officer

Officer
90,616
25.09
US$2,274,007 		90,616 25.09 US$2,274,007
2026-07-09 2026-07-07 PlS Planned sale
1.6
Horn Kinney

CHIEF BUSINESS OFFICER

Officer
1,092 -100.0%
25.00
US$27,300 		1,092 -100.0% 25.00 US$27,300
2026-07-07 2026-07-07 PlS Planned sale
Barchas Isaac
Non-Executive Director
16,906 -13.5%
24.20
US$409,125 		16,906 -13.5% 24.20 US$409,125
2026-07-07 2026-07-07 PrS Proposed sale
1.6
Horn Kinney

Officer

Officer
1,092
25.00
US$27,300 		1,092 25.00 US$27,300
2026-07-07 2026-07-06 PlS Planned sale
Barchas Isaac
Non-Executive Director
83,094 -39.9%
24.11
US$2,003,396 		83,094 -39.9% 24.11 US$2,003,396
2026-07-06 2026-07-06 PrS Proposed sale
ABHMC II, LLC

Shareholder
100,000
23.61
US$2,361,000 		100,000 23.61 US$2,361,000
2026-07-07 2026-07-02 PlS Planned sale
2.2
Lechleider Robert

Chief Medical Officer

Officer
16,072 -50.4%
23.44
US$376,728 		16,072 -50.4% 23.44 US$376,728
2026-07-07 2026-07-02 PlS Planned sale
2.2
Lechleider Robert

Chief Medical Officer

Officer
16,214 -33.7%
22.76
US$369,031 		16,214 -33.7% 22.76 US$369,031
2026-07-07 2026-07-02 PlS Planned sale
2.2
Lechleider Robert

Chief Medical Officer

Officer
22,714 -32.1%
21.95
US$498,572 		22,714 -32.1% 21.95 US$498,572
2026-07-02 2026-07-02 PlS Planned sale
Barchas Isaac
Non-Executive Director
24,335 -10.5%
23.33
US$567,736 		24,335 -10.5% 23.33 US$567,736
2026-07-02 2026-07-02 PlS Planned sale
Barchas Isaac
Non-Executive Director
75,665 -24.5%
22.35
US$1,691,113 		75,665 -24.5% 22.35 US$1,691,113
2026-07-02 2026-07-02 PrS Proposed sale
ABHMC II, LLC

Shareholder
100,000
21.49
US$2,149,000 		100,000 21.49 US$2,149,000
2026-07-02 2026-07-02 PrS Proposed sale
2.2
Lechleider Robert

Officer

Officer
55,000
21.60
US$1,188,000 		55,000 21.60 US$1,188,000
2026-07-02 2026-06-30 PlS Planned sale
Barchas Isaac
Non-Executive Director
101,050 -24.7%
21.12
US$2,134,176 		101,050 -24.7% 21.12 US$2,134,176
2026-06-30 2026-06-30 PrS Proposed sale
Arsenal Bridge Venture II-B, LLC

Shareholder
1,050
21.04
US$22,092 		1,050 21.04 US$22,092
2026-06-30 2026-06-30 PrS Proposed sale
ABHMC II, LLC

Shareholder
100,000
21.04
US$2,104,000 		100,000 21.04 US$2,104,000
2026-06-29 2026-06-25 PlS Planned sale
2.2
Lechleider Robert

Chief Medical Officer

Officer
14,420 -47.7%
20.66
US$297,917 		14,420 -47.7% 20.66 US$297,917
2026-06-29 2026-06-25 PlS Planned sale
2.2
Lechleider Robert

Chief Medical Officer

Officer
40,580 -57.3%
19.56
US$793,745 		40,580 -57.3% 19.56 US$793,745
2026-06-25 2026-06-25 PrS Proposed sale
2.2
Lechleider Robert

Officer

Officer
55,000
19.73
US$1,085,150 		55,000 19.73 US$1,085,150
2026-06-17 2026-06-15 PlS Planned sale
3.3
Rosett Max

Chief Financial Officer

Officer
60,000 -52.6%
18.23
US$1,093,800 		60,000 -52.6% 18.23 US$1,093,800
2026-06-15 2026-06-15 PrS Proposed sale
3.3
Rosett Max

Officer

Officer
60,000
18.63
US$1,117,800 		60,000 18.63 US$1,117,800
2026-06-09 2026-06-05 B Purchase
2.9
BIENAIME JEAN JACQUES
Non-Executive Director
1,000 +2.4%
19.27
US$19,270 		1,000 +2.4% 19.27 US$19,270
2026-06-09 2026-06-05 B Purchase
2.9
BIENAIME JEAN JACQUES
Non-Executive Director
1,000 +2.4%
19.27
US$19,270 		1,000 +2.4% 19.27 US$19,270
2026-06-09 2026-06-05 B Purchase
2.9
BIENAIME JEAN JACQUES
Non-Executive Director
3,500 +9.0%
19.46
US$68,110 		3,500 +9.0% 19.46 US$68,110
2026-06-09 2026-06-05 B Purchase
2.9
BIENAIME JEAN JACQUES
Non-Executive Director
3,500 +9.0%
19.46
US$68,110 		3,500 +9.0% 19.46 US$68,110
2026-06-09 2026-06-05 B Purchase
2.9
BIENAIME JEAN JACQUES
Non-Executive Director
6,000 +18.2%
19.48
US$116,880 		6,000 +18.2% 19.48 US$116,880
2026-06-09 2026-06-05 B Purchase
2.9
BIENAIME JEAN JACQUES
Non-Executive Director
6,000 +18.2%
19.48
US$116,880 		6,000 +18.2% 19.48 US$116,880
2026-06-09 2026-06-05 S Sale
2.9
BIENAIME JEAN JACQUES
Non-Executive Director
10,000 -23.3%
19.41
US$194,100 		10,000 -23.3% 19.41 US$194,100
2026-06-09 2026-06-05 S Sale
2.9
BIENAIME JEAN JACQUES
Non-Executive Director
10,000 -23.3%
19.41
US$194,100 		10,000 -23.3% 19.41 US$194,100
2026-06-09 2026-06-05 S Sale
2.9
BIENAIME JEAN JACQUES
Non-Executive Director
500 -1.2%
19.44
US$9,720 		500 -1.2% 19.44 US$9,720
2026-06-09 2026-06-05 S Sale
2.9
BIENAIME JEAN JACQUES
Non-Executive Director
500 -1.2%
19.44
US$9,720 		500 -1.2% 19.44 US$9,720
2026-05-19 2026-05-15 B Purchase
2.9
BIENAIME JEAN JACQUES
Non-Executive Director
5,000 +13.0%
20.70
US$103,500 		5,000 +13.0% 20.70 US$103,500
2026-04-03 2026-04-02 PlS Planned sale
2.2
Higgins Jack

Chief Scientific Officer

Officer
9,438 -30.0%
21.64
US$204,238 		9,438 -30.0% 21.64 US$204,238
2026-04-03 2026-04-02 PlS Planned sale
3.3
Rosett Max

Chief Financial Officer

Officer
1,344 -2.4%
22.48
US$30,213 		1,344 -2.4% 22.48 US$30,213
2026-04-03 2026-04-02 PlS Planned sale
3.3
Rosett Max

Chief Financial Officer

Officer
63,656 -53.5%
21.91
US$1,394,703 		63,656 -53.5% 21.91 US$1,394,703
2026-04-03 2026-04-02 PrS Proposed sale
3.3
Rosett Max

Officer

Officer
65,000
21.92
US$1,425,085 		65,000 21.92 US$1,425,085
2026-04-02 2026-04-02 PrS Proposed sale
3.3
Rosett Max

Officer

Officer
65,000
72.67
US$4,723,550 		65,000 72.67 US$4,723,550
2026-04-02 2026-04-02 PrS Proposed sale
2.2
Higgins Jack

Officer

Officer
9,438
21.64
US$204,238 		9,438 21.64 US$204,238
2026-03-31 2026-03-27 B Purchase
3.3
SIEGALL CLAY B

President and CEO

Executive Director
25,450 +3.8%
19.67
US$500,602 		25,450 +3.8% 19.67 US$500,602
2026-03-23 2026-03-23 S Sale
1.8
WAGENHEIM PHILIP
Non-Executive Director
28,200 -7.6%
20.65
US$582,330 		28,200 -7.6% 20.65 US$582,330
2026-03-23 2026-03-20 S Sale
1.8
WAGENHEIM PHILIP
Non-Executive Director
36,800 -9.1%
20.47
US$753,296 		36,800 -9.1% 20.47 US$753,296
2026-03-20 2026-03-20 PrS Proposed sale
1.8
WAGENHEIM PHILIP

Director

Non-Executive Director
65,000
20.81
US$1,352,640 		65,000 20.81 US$1,352,640
2026-03-12 2026-03-11 B Purchase
2.9
BIENAIME JEAN JACQUES
Non-Executive Director
1,000 +2.7%
21.55
US$21,550 		1,000 +2.7% 21.55 US$21,550
2026-03-12 2026-03-10 B Purchase
2.9
BIENAIME JEAN JACQUES
Non-Executive Director
1,000 +2.7%
22.12
US$22,120 		1,000 +2.7% 22.12 US$22,120
2025-12-30 2025-12-30 B Purchase
3.3
SIEGALL CLAY B

President and CEO

Executive Director
4,729 +0.7%
21.15
US$100,018 		4,729 +0.7% 21.15 US$100,018
2025-12-23 2025-12-22 PlS Planned sale
Barchas Isaac
Non-Executive Director
11,251 -0.6%
22.34
US$251,347 		11,251 -0.6% 22.34 US$251,347
2025-12-23 2025-12-22 PlS Planned sale
Barchas Isaac
Non-Executive Director
371,949 -15.4%
21.72
US$8,078,732 		371,949 -15.4% 21.72 US$8,078,732
2025-12-22 2025-12-19 B Purchase
3.3
SIEGALL CLAY B

President and CEO

Executive Director
7,278 +0.9%
20.48
US$149,053 		7,278 +0.9% 20.48 US$149,053
2025-12-22 2025-12-19 B Purchase
3.5
Tsai Philip

Chief Technical Officer

Officer
10,000 +30.0%
20.49
US$204,900 		10,000 +30.0% 20.49 US$204,900
2025-12-18 2025-12-18 B Purchase
3.3
SIEGALL CLAY B

President and CEO

Executive Director
46,511 +5.8%
21.50
US$999,986 		46,511 +5.8% 21.50 US$999,986
2025-06-03 2025-06-03 B Purchase
2.9
BIENAIME JEAN JACQUES
Non-Executive Director
5,000 +15.9%
9.38
US$46,900 		5,000 +15.9% 9.38 US$46,900
2025-03-26 2025-03-26 B Purchase
3.3
SIEGALL CLAY B

President and CEO

Executive Director
137,100 +20.5%
7.29
US$999,459 		137,100 +20.5% 7.29 US$999,459
2025-03-26 2025-03-25 B Purchase
2.9
BIENAIME JEAN JACQUES
Non-Executive Director
7,800 +33.0%
7.78
US$60,684 		7,800 +33.0% 7.78 US$60,684
2025-03-25 2025-03-24 B Purchase
2.9
BIENAIME JEAN JACQUES
Non-Executive Director
7,000 +42.1%
8.21
US$57,470 		7,000 +42.1% 8.21 US$57,470
2025-03-25 2025-03-24 B Purchase
3.5
Tsai Philip

Chief Technology Officer

Officer
12,300 +58.6%
8.42
US$103,566 		12,300 +58.6% 8.42 US$103,566
2025-02-03 2025-01-31 B Purchase
3.3
SIEGALL CLAY B

President and CEO

Executive Director
150,000 +28.9%
7.75
US$1,162,500 		150,000 +28.9% 7.75 US$1,162,500
2024-11-25 2024-11-22 B Purchase
3.3
SIEGALL CLAY B

President and CEO

Executive Director
33,943 +7.0%
9.78
US$331,918 		33,943 +7.0% 9.78 US$331,918
2024-11-25 2024-11-21 B Purchase
3.3
SIEGALL CLAY B

President and CEO

Executive Director
66,057 +15.7%
9.54
US$630,263 		66,057 +15.7% 9.54 US$630,263
2024-11-25 2024-11-21 B Purchase
2.2
Lechleider Robert

Chief Medical Officer

Officer
15,805 +inf%
9.48
US$149,800 		15,805 +inf% 9.48 US$149,800
2024-11-25 2024-11-21 B Purchase
3.5
Tsai Philip

Chief Technology Officer

Officer
21,000 +inf%
9.43
US$198,030 		21,000 +inf% 9.43 US$198,030
2024-09-20 2024-09-19 S Sale
3.3
Rosett Max

Chief Financial Officer

Officer
14,380 -23.2%
16.01
US$230,224 		14,380 -23.2% 16.01 US$230,224
2024-09-19 2024-09-19 PrS Proposed sale
3.3
Rosett Max

Officer

Officer
14,380
16.01
US$230,211 		14,380 16.01 US$230,211
2024-08-19 2024-08-16 B Purchase
2.9
BIENAIME JEAN JACQUES
Non-Executive Director
7,000 +72.8%
13.94
US$97,608 		7,000 +72.8% 13.94 US$97,608
2024-08-19 2024-08-15 S Sale
2.2
Higgins Jack

Chief Scientific Officer

Officer
3,524 -18.0%
13.93
US$49,072 		3,524 -18.0% 13.93 US$49,072
2024-08-15 2024-08-15 PrS Proposed sale
2.2
Higgins Jack

Officer

Officer
3,524
13.93
US$49,073 		3,524 13.93 US$49,073
Explore more

More insider trading research around Immunome Inc

More insider trades in United States
Similar Healthcare companies with insider activity
More Pharmaceuticals & Medical Research companies with insider activity
More Biotechnology & Medical Research companies with insider activity
Insider trading in North America